Altimmune, Inc. shares rise 4.64% intraday after completing enrollment in HepTcell Phase II clinical trial.

Altimmune, Inc. rose 4.64% in intraday trading, with the company being a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The company has completed the enrollment in its Phase II clinical trial of HepTcell.